Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | POLA1 | P09884 | 1/20 | 0.68 |
| ▸ | POLD1 | P28340 | 1/20 | 0.68 |
| ▸ | TK1 | P04183 | 6/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586988 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL3031874 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL265387 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL77582 | 1.00 | POLB (0.68) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL154177 | 0.98 | POLB (0.65) | POLBPOLA1POLD1TK1BCHE | |
| Triphosphate SCHEMBL27892350 | 0.95 | POLB (0.61) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL28961478 | 0.94 | POLB (0.61) | POLBPOLA1POLD1TK1 | |
| SCHEMBL3446958 | 0.93 | POLB (0.60) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL8859644 | 0.93 | POLB (0.61) | POLBPOLA1POLD1TK1BCHE | |
| SCHEMBL28543730 | 0.91 | POLB (0.59) | POLBPOLA1POLD1TK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022083686-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2022-04-28 | — | — | WO | disclosed |
| US-11117921-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | IsoPlexis Corporation (US) | 2021-09-14 | — | — | US | disclosed |
| US-10844430-B2 | DNA sequencing reaction additive | QIAGEN SCIENCES, LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190226018-A1 | SEQUENCING ADDITIVE | IsoPlexis Corporation | 2019-07-25 | — | — | US | disclosed |
| US-10273539-B2 | Methods of using nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170137878-A1 | METHODS OF USING NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844430-B2 | DNA sequencing reaction additive | RNGTT, NSUN2, NT5C3B | POLB 18/4885POLA1 147/4885POLD1 89/4885 |
| US-20190226018-A1 | SEQUENCING ADDITIVE | NT5C3B, RNGTT, NSUN2 | POLB 42/4885POLA1 310/4885POLD1 239/4885 |
| US-11117921-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | RNGTT, NT5C3B, DUT | POLB 51/4885POLA1 300/4885POLD1 185/4885 |
| US-10273539-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | POLB 32/4885POLA1 216/4885POLD1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.